Abvc biopharma provides updates on adhd phase iib clinical study

Fremont, ca, aug. 23, 2023 (globe newswire) -- via newmediawire  – abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the company's adhd phase iib clinical study. these subjects were enrolled at the university of california san francisco (ucsf) medical center and five taiwanese medical centers.
ABVC Ratings Summary
ABVC Quant Ranking